Supply of Herron Sennesoft and Chemists' Own Natural Laxative with Softener by Aspen Pharma Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, aims to regulate therapeutic goods in Australia, ensuring their safety, quality, and efficacy. A notable addition to this Act is the introduction of sections 14 and 14A, which facilitate the issuance of consents for the supply of therapeutic goods that do not fully comply with certain regulations, provided that public health and safety are not compromised. The policy objective behind these sections is to balance regulatory flexibility with the need to protect public health, allowing for the supply of therapeutic goods that meet most, but not all, regulatory standards under specific conditions. This approach provides a pragmatic solution to certain supply chain issues while maintaining the overarching goal of safeguarding public health. In the case of the gazetted notice dated 5 December 2012, Mayada Kayali, as a delegate of the Secretary to the Department of Health and Ageing, granted consent for Aspen Pharma Pty Ltd to supply two specific therapeutic goods that do not fully comply with the limits for sennosides content as stipulated in Therapeutic Goods Order No. 78. This consent is subject to conditions ensuring that the products remain within specified limits for sennosides content at both release and expiry, thereby ensuring that the products' quality and efficacy are not adversely affected. This exemplifies the Act's intent to permit the supply of therapeutic goods under controlled conditions, thereby facilitating access while upholding public health standards.

Scope and Application

The Therapeutic Goods Act 1989 applies to therapeutic goods, including medicines, medical devices, and related products within Australia. This legislation governs the regulation and oversight of these goods to ensure they meet safety, quality, and efficacy standards. The Act applies to persons and entities involved in the manufacturing, importing, supplying, advertising, and exporting of therapeutic goods. It also applies to the conduct and transactions associated with these activities, aiming to protect public health by regulating the therapeutic goods market. The Act's jurisdiction extends across the Commonwealth of Australia, with the Therapeutic Goods Administration (TGA) being the primary regulatory body responsible for its enforcement. However, the Act may include exclusions or exemptions, such as for research purposes or specific goods under certain conditions. Additionally, the Act allows for the creation of subordinate instruments, such as therapeutic goods orders, which can extend or restrict its application by setting specific requirements or conditions for certain therapeutic goods.

Key Provisions

Section 14 and 14A of the Therapeutic Goods Act 1989 provide the framework for the Secretary to the Department of Health and Ageing to grant consent for the supply of therapeutic goods that do not fully comply with certain specifications. In this instance, section 14A has been exercised to allow Aspen Pharma Pty Ltd to supply two specific products: HERRON SENNESOFT tablet blister pack (AUST R 82877) and CHEMISTS’ OWN NATURAL LAXATIVE WITH SOFTENER tablet blister pack (AUST R 90442). These products do not meet the requirements of Therapeutic Goods Order No. 78 concerning the limits for the content of sennosides in the finished product specifications. However, this consent is conditional, as stipulated in section 15(1) of the Act, and will only be valid if certain conditions are met. The primary condition imposed by the Act requires that the content of sennosides in the finished products must fall within specific percentages at both release and expiry. At the point of release, the content must be between 97.5% and 110.0%. At expiry, the permissible range is slightly broader, between 92.5% and 110.0%. These limits are set to ensure that the products remain effective and safe for consumer use, despite not fully meeting the original specifications outlined in Therapeutic Goods Order No. 78. Any other requirements of Therapeutic Goods Order No. 78 must still be adhered to, ensuring that the products meet all other necessary standards and criteria. The obligations imposed by this consent extend to Aspen Pharma Pty Ltd, the entity granted permission to supply the products under these conditions. They must ensure that the products meet the specified sennosides content limits and comply with all other relevant requirements of Therapeutic Goods Order No. 78. This includes maintaining thorough records and documentation to demonstrate compliance, as well as being prepared to provide this information to the Department of Health and Ageing upon request. Failure to comply with the conditions set out in this consent could result in serious legal and financial consequences. Under the Therapeutic Goods Act 1989, breaches of the Act's provisions, including non-compliance with the conditions of consent, can lead to civil or criminal penalties. While the exact penalties are not specified in this particular consent notice, generally under the Act, civil penalties can include fines up to $222,200 for individuals and significantly higher amounts for corporations. Criminal penalties can include fines and imprisonment, with maximum penalties varying depending on the severity and nature of the breach. Therefore, it is crucial that Aspen Pharma Pty Ltd adheres strictly to the conditions to avoid any potential legal repercussions.